Academic Appointments
- Assistant Professor of Neurology
Current Administrative Positions
- Deputy Director, Division of Neuro-Oncology
Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors.
Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.Departmental Appointments
- Department of Neurology
Division of Neuro-oncology
Education and Training
- Universidad Federal Do Parana
- Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Residency: Memorial Sloan-Kettering Cancer Center
Centers / Institutes / Programs
- Herbert Irving Comprehensive Cancer Center
Links
NIH Grants
PHASE II TRIAL OF PEMBROLIZUMAB AND REIRRADIATION IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)
Apr 8 2019 - Apr 8 2024
A PHASE 1B/2 STUDY OF FT-2102 IN PATIENTS WITH ADVANCED SOLID TUMORS AND GLIOMAS WITH AN IDH1 MUTATION (P&S Industry Clinical Trial)
Mar 29 2019 - Mar 29 2024
SINGLE PATIENT ACCESS (COMPASSIONATE USE): PF-06840003 FOR MALIGNANT GLIOMAS (SINGLE PATIENT IND) (P&S Industry Clinical Trial)
Nov 28 2018 - Nov 28 2023
A PHASE II, OPEN LABEL, SINGLE ARM STUDY OF NIVOLUMAB FOR RECURRENT OR PROGRESSIVE IDH MUTANT GLIOMAS WITH PRIOR EXPOSURE TO ALKYLATING AGENTS. (P&S Industry Clinical Trial)
May 29 2018 - May 29 2023
A PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, COMBINED WITH TOCA FC VERSUS STANDARD OF CARE IN SUBJECTS UNDERGOING PLANNED RESECTION FOR RECURRENT GLIOBLASTOMA OR ANAPLASTIC ASTROCYTOMA. (P&S Industry Clinical Trial)
May 17 2016 - May 17 2021
A PHASE 1/2 STUDY OF SL-701, A SUBCUTANEOUSLY INJECTED MULTIVALENT GLIOMA- ASSOCIATED ANTIGEN VACCINE, IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Dec 18 2014 - Dec 18 2019
PHASE II STUDY OF BEVACIZUMAB AND TEMOZOLOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)
Oct 20 2014 - Oct 20 2019
AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)
Jul 26 2013 - Jul 26 2018
A PHASE I/II TRIAL OF EVEROLIMUS (RAD001) AND SORAFENIB IN PATIENTS WITH HIGH-GRADE GLIOMAS (P&S Industry Clinical Trial)
Jun 17 2013 - Jun 17 2018
PHASE II TRIAL OF BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMAS (P&S Industry Clinical Trial)
Mar 22 2013 - Mar 22 2018
A PHASE III CLINICAL TRIAL EVALUATING DCVAX-L, AUTOLOGOUS DENDRITIC CELLS PULSED WITH TUMOR LYSATE ANTIGEN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)
Dec 11 2012 - Dec 11 2017
CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION (INTELLANCE 1) (RTOG 3508) (Private)
Sep 1 2015 - Aug 31 2016
RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)
Jan 1 2009 - Dec 31 2014
RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)
Jan 1 2009 - Dec 31 2014
